Navigation Links
Singapore scientists exploit knowledge of p53 for increasing specificity of cancer treatments
Date:5/24/2010

Researchers from the p53 Laboratory of Singapore's Agency for Science, Technology and Research (A*STAR), have made a finding that makes feasible a unique method of cancer treatment. Their work, published online in the leading journal Cell Death and Differentiation today , offers new insight on how to tap on the properties of p53, the 'guardian of the genome' , to more effectively kill cancer cells while sparing normal cells.

The researchers, led by Dr Cheok Chit Fang and Prof David Lane, the co-discoverer of the p53 gene in 1979, achieved this by exploiting one of the key functions of p53 the control of the cell cycle.

Activating p53 halts the cell cycle and prevents endoreduplication, a process by which a cell accumulates excess genetic material by duplicating its existing genetic material without actually dividing. If endoreduplication happens in human cells, they die. Deliberately inducing endoreduplication in cancer cells through chemical means has been explored as a means of killing off cancer cells. However, as the drugs used are not highly specific to cancer cells, many normal cells are also killed in the process.

Fortunately, in many cancers, the cancer cells lack working copies of p53. By using a drug that activates p53 in healthy cells and temporarily induces the cells to stop the production of genetic material, endoreduplication is prevented. Cancer cells which lack working copies of p53 are thus left susceptible to a second drug that induces endoreduplication, resulting in tumour-specific killing. The activation of p53 is reversible and the normal cells resume their function once the cancer cells have been killed.

Said Prof David Lane, Director of the p53 Laboratory and A*STAR's Chief Scientist, "We are proposing a unique combination of drugs which may have therapeutic benefits and could potentially alleviate the side effects of currently available cancer treatments. The clinical approval of nutlin or nutlin-like drugs will allow such exciting concepts to be tested in the clinic. We hope that this work encourages further breakthroughs in p53 research and brings more efficient and cost-effective treatments for the millions of cancer patients worldwide."

Dr Cheok said, "One the most difficult problems in treating cancer is ensuring that normal, healthy cells are not killed over the course of treatment. Many of the currently available methods of treatment, such as chemotherapy and radiation therapy, damage normal cells in the process of killing cancer cells. We are using our knowledge of p53 to overcome this difficulty."

Dr Cheok was among the first few Singaporeans to embark on a PhD scholarship from A*STAR in 2001 . After receiving her PhD from the University of Oxford, she began her post-doctoral training under the tutelage of Prof Lane in 2006. She is also an Assistant Professor and a Senior Research Fellow at the Department of Biochemistry at the Yong Loo Lin School of Medicine, NUS.

Prof Lane added, "We are proud of Chit Fang for having made this significant finding so early in her scientific career. It gives me great pleasure to have her as part of my team working on deepening our understanding of how to use basic science findings to develop new therapies."


'/>"/>

Contact: Joshua Tan
joshua_tan@a-star.edu.sg
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Related biology news :

1. Singapore program to provide clinical insight; showcase for regional research
2. Singapore scientists join international study of 10,000 vertebrates genomes
3. MINDEF, NTU join hands to boost Singapores defense R&D capabilities
4. New Singapore-France research alliance to develop state-of-the-art nanotechnologies
5. Facile synthesis of nanoparticles with multiple functions advanced in Singapore
6. Singapore nanotechnology combats fatal brain infections
7. Singapore scientists elected into National Academy of Sciences
8. Alzheimers, asthma, cancer, malaria and TB focus of new Singapore grants
9. Singapore scientists synthesize gold to shed light on cells inner workings
10. Singapore researchers first to transform carbon dioxide into methanol
11. First tri-continuous mesoporous Silica complex structure developed in Singapore
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: